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Background and purpose   Wear debris from conventional total 
hip arthroplasty (THA) induces chromosomal aberrations and 
DNA damage, which may promote cancerogenesis. A long latent 
period is required for solid tumors. We therefore re-analyzed a 
large THA cohort for cancer.
Patients and methods   We updated a cohort of 24,636 patients 
with primary osteoarthritis and metal-on-polyethylene THA who 
had been entered in the Finnish Arthroplasty Register between 
1980 and 1995, and linked it to the Finnish Cancer Registry for 
cancer risk assessment up to 2005. The mean follow-up time was 
13 years. The numbers of cancer cases observed were compared 
with expected rates based on incidence in the general population.
Results   The standardized incidence ratio (SIR) for the whole 
follow-up period was 0.95 (95% confidence interval (CI): 0.92–
0.97). After 10 years of follow-up, the SIR was equal to that in the 
normal population (SIR = 0.98, 95% CI: 0.94–1.03). Incidence of 
lung cancer was low throughout the follow-up time and that of 
prostate cancer was slightly elevated. The incidence rates for all 
other forms of cancer did not deviate significantly from those in 
the normal population.
Interpretation   We found no increased cancer risk in patients 
with conventional THA after an average of 13 years and up to 25 
years of follow-up. 

Corrosion and wear of THA liberates metal, polyethylene, and 
methacrylate particles. According to post-mortem and in vivo 
studies, such metal particles are widely dispersed in the body 
and have been found in the liver, the spleen, and in local and 
distant lymph nodes (Langkamer et al. 1992, Case et al. 1994, 
Eng et al. 1997, Shea et al. 1997, Urban et al. 2000, 2004). 
Thus, patients with metal-on-polyethylene (MP) bearings are 
permanently exposed to Cr, Co, and Ti ions more extensively 
than healthy controls (Jacobs et al. 1998, Savarino et al. 2002, 
MacDonald et al. 2003, Rasquinha et al. 2006).
Both in vivo and in vitro studies have shown chromosomal 
aberrations and DNA damage in association with debris from 
CoCr and TiAlV prostheses. Bone marrow adjacent to the worn 
implant was found to show an increased number of chromatid 
breaks and gaps (Case et al. 1996). At revision THA, patients 
with mixed types of CoCr prostheses had a 2.5-fold increase 
in  peripheral  blood  lymphocytes  with  aneuploidy  and  3.5 
fold more chromosomal translocations than at primary THA 
(Doherty et al. 2001). Wear debris from worn hip and knee 
prostheses in human tissue cultures has been found to damage 
chromosomes in a dose-dependent manner, which was specific 
to the type of metal. A correlation was found between Co and 
Cr concentrations on the one hand and chromosomal breakage 
and aneuploidy on the other; similarly, there was a correlation 
between Ti concentrations and aneuploidy (Daley et al. 2004). 
Davies et al. (2005) showed that synovial fluid from revised 
CoCr metal-on-metal (MM) and MP prostheses caused DNA 
damage to human fibroblast culture cells, which was believed 
to be a synergistic effect of Co and Cr ions. Wear debris from a 
worn TiAlV MP prosthesis has been found to produce chromo-
somal instability in human fibroblast cell cultures (Coen et al. 
2003). Further genomic instability was evident when the prog-
eny of the cells were exposed to low doses of wear debris. Chro-
mosomal aberrations associated with metallic ions can be pre-
dictive of cancerogenesis (Bonassi et al. 2000) and an increased 
risk of cancer in THA patients. Latent periods of 10 or more 
years are required for the development of particle-, virus-, or 
industrial metal-induced cancers (zur Hausen 1996, Yates et al. 
1997, Anttila et al. 1998). We investigated the long-term risks 
for all and site-specific cancers in primary THA patients with 
MP prostheses by updating our previous cohort study from the 
Finnish Endoprosthesis Register (Paavolainen et al. 2000). 78  Acta Orthopaedica 2010; 81 (1): 77–81
Patients and methods
The data from the Finnish Arthroplasty Register was linked 
with that from the Finnish Cancer Registry, and records of all 
cancer cases were obtained from 1980 through 2005. The orig-
inal cohort comprised 33,694 patients, 24,636 of whom were 
operated on for primary osteoarthritis (OA). All patients were 
provided with MP prostheses, and 71% of the femoral compo-
nents and 65% of the acetabular components were cemented. 
The stem material was cobalt chrome molybdenum (CoCrMo) 
in about 40% of the prostheses, titanium aluminium vanadium 
(TiAlV) in 36%, and stainless steel (SS) in 24% (Nevalainen 
et al. 2000).
The patients were followed up for cancer incidence from the 
date of first operation until death, or until 31 December 2005. 
The follow-up time was up to 25 years with a mean of 12.6 
years. The follow-up was not stopped at the date of first diag-
nosis of cancer, but all primary cancers diagnosed during the 
follow-up period were counted as observed cases. The numbers 
of observed cases for each cancer and person-years at follow-
up were stratified by sex, calendar period and 5-year age group, 
and follow-up time since the operation. The expected number 
of each cancer type was calculated by applying the number of 
person-years in each stratum to the corresponding cancer inci-
dence rate in the Finnish population. The calendar periods used 
were 1980–1986, 1987–1993, 1994–1999, and 2000–2005, and 
the follow-up categories were 0–2, 3–9, 10–20, and > 20 years 
since the operation. Only 97 patients (0.04%) were followed for 
more than 20 years. The relative risk of cancer was expressed 
as the ratio of observed and expected number of cases, i.e. stan-
dardized incidence ratio (SIR). The 95% confidence intervals 
(95% CIs) were defined assuming that the number of observed 
cases followed a Poisson distribution.
Results
The cohort yielded 310,341 person-years, which is approxi-
mately twice as much as in the previous analysis (Paavolainen 
et al. 2000). The proportion of male patients was 38% (Table 
1). Altogether, 13,324 patients (54%) had died before the end 
of 2005. There were no losses to follow-up.
The overall SIR for all-site cancers was 0.95 (95% CI: 0.92–
0.97) (Table 2). After the first 2 postoperative years with very 
low all-site cancer incidence (SIR = 0.80; 95% CI: 0.73–0.87), 
the SIR rose to 0.97 (95% CI: 0.94–1.00) (Table 3).
After 10 and 20 years of follow-up, the all-site cancer inci-
dence was similar to that in the general population with a 
SIR of 0.98 (95% CI: 0.94–1.03) and 0.93 (95% CI: 0.75–
1.12), respectively. Female patients had higher SIR values 
than male patients during the first 2 years (0.91 (95% CI: 
0.81–1.01) vs. 0.69 (95% CI: 0.60–0.78)), and between years 
3 and 9 postoperatively (0.98 (95% CI: 0.92–1.02) vs. 0.93 
(95% CI: 0.88–0.98)). These higher SIR values were mainly 
due to breast cancer and female genital cancers. The corre-
sponding SIR values in the general population were, how-
ever, similar from the beginning and throughout the whole 
study period (Table 3). Site-specific cancers, except for lung, 
colon,  prostate  cancer  and  non-Hodgkin’s  lymphoma,  had 
SIR values that were similar to those in the normal population 
(Table 2). Lung cancer incidence was low in the male patients 
throughout the whole follow-up period (with SIR values of 
0.35–0.84) (Table 3).
SIR for kidney cancer was relatively high already during 
the  first  postoperative  year  and  increased  slightly  thereaf-
Table 1. Numbers of patients (n) by age at operation, and number of 
person-years at end of follow-up
Age    Men   Women 
  n    Person-years    n    Person-years
 
15–29   10    35   11    44
30–44    156   784   168    906
45–59    2,060   11,144   2,214    11,796
60–74    5,751   57,484   9,214    83,132
≥ 75   1,502   43,861   3,550    101,155
Total   9,479   113,308   15,157    197,033
Table 2. Observed (Obs) numbers of cancer cases and standard-
ized incidence ratios (SIRs) with 95% confidence intervals, by site
Primary site   Obs   SIR   95% CI
All sites   4846    0.95    0.92–0.97 a
Lip   50    1.19   0.88–1.56
Mouth, pharynx   104    1.09    0.89–1.30
Esophagus   49    0.81    0.60–1.06
Stomach   245     0.95    0.84–1.07
Colon   310    0.89    0.79–0.99 b
Rectum   193    0.91    0.79–1.04
Liver   65     0.87    0.67–1.11
Gall bladder   86    1.01    0.81–1.24
Pancreas   201    0.90    0.78–1.02
Larynx   19    0.80    0.48–1.25
Lung   368    0.65    0.58–0.71 a
Breast   515    1.00    0.92–1.08
Uterus, cervix   28    1.03    0.68–1.48
Uterus, corpus   134    0.94    0.79–1.10
Ovary   86    0.94    0.75–1.16
Prostate   843    1.09    1.02–1.16 b
Kidney   180    1.08    0.93–1.24
Bladder,ureter, urethra   222    0.98    0.86–1.11
Melanoma   97     0.99    0.80–1.20
Skin   279    1.07    0.95–1.20
Brain/nervous system   103    0.97    0.79–1.16
Thyroid   38    1.06    0.75–1.45
Bone   3     0.72    0.15–2.10
Connective tissue   24    0.90    0.58–1.34
Non-Hodgkin’s lymphoma   167    0.92    0.79–1.06
Nodal non-Hodgkin’s lymphoma   98    0.81    0.66–0.98 b
Hodgkin’s lymphoma   13    1.26    0.67–2.15
Myeloma   90    1.14    0.92–1.40
Leukemia   96     0.85    0.69–1.03
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ter (Tables 2 and 3). A slight excess of prostate cancers was 
observed between years 10 and 19 (SIR = 1.14) and also during 
the whole follow-up (SIR = 1.09) (Table 3). The SIR for bone 
and soft tissue sarcomas was 0.77 (95% CI: 0.51–1.12).
A slight increase in hematopoetic cancers (SIR = 1.11) was 
observed between years 10 and 19 postoperatively, which was 
due to an increase in multiple myelomas and Hodgkin lympho-
mas. SIRs for all hematopoetic cancers were similar to those 
in the normal population (0.97). The SIRs for non-Hodgkin’s 
lymphomas and leukemia remained below (1.00) during the 
whole follow-up time, whereas those for multiple myeloma 
ranged from 1.00 to 1.19, and those for Hodgkin’s lymphoma 
from 1.13 to 1.38 after the twentieth postoperative year.
Discussion
The patients in our cohort were exposed to the degradation 
products of the most common metal alloys used: CoCrMo, 
TiAlV, or SS alloy, but cement usage and different metal com-
positions and cancer risk were not studied because these data 
were not available per hip or per patient in the study material. 
The overall cancer risk seen in this study (SIR = 0.95) was 
the same level (SIR = 0.98) to that seen in a large meta-analy-
sis on THA patients with 1,094 000 person-years and oper-
ated on for all indications, but with a mean follow-up time 
of only 6 years  (Onega et al. 2006). The same findings were 
reported by Goldachre et al. (2005) from the UK after an aver-
age of 8 years of follow-up of 33,691 patients who were oper-
ated for all indications. The SIR of 0.92 in our cohort during 
the first 10 years is equal to that (0.93) observed in a Nordic 
meta-analysis in patients who were operated on for OA with 
374,000 person-years and with a mean follow-up time of 8 
years (Visuri et al. 2003). In one study, OA has been reported 
to be associated with low cancer co-morbidity: Thomas et al. 
(2000) reported a low all-site cancer incidence (0.85 for males 
and 0.83 for females) in patients with all forms of OA in a 
Scottish cohort.
Pre-screening  of  our  patients  for  surgery  decreased  the 
cancer incidence in a comparison with the normal population   
approximately for 10 years indicating a long latent period. We 
found 20% less cancer cases than in a comparative sample 
of the general Finnish population during the 2 postoperative 
years, but after 11 years of follow-up the cancer incidence rate 
were equalized.
Lung cancer incidence in the male patients was low through-
out the whole follow-up period. It is well known that tobacco 
smoking is the cause of lung cancer in 90% of cases (Tyczyn-
sky et al. 2003). A low incidence of lung cancer was reported 
in a meta-analysis involving THA patients operated on for pri-
mary osteoarthritis (SIR = 0.69) (Visuri et al. 2003). In THA 
patients operated on for all indications, the SIR for lung cancer 
was found to be 0.82 (Onega et al. 2006), which was similar 
to the value from a large British cohort (0.86) (Goldachre et 
al. 2005). In 1,495 male Swedish constructors who smoked, 
the risk of severe osteoarthritis of the hip requiring surgery 
was found to be lower than in non-smokers or ex-smokers 
(Järvholm et al. 2005). Also, a significantly lower risk of hip 
osteoarthritis was found in 210 men who were current cigarette 
smokers than in men who had never smoked and who were 
listed for THA (Cooper et al. 1998). This association was not 
observed in women. Vingård et al. (1997) observed a reversed 
risk in 230 women who had undergone a THA operation.  
Special interest lay in the occurrence of hematopoetic malig-
nancies, given the high number of these cancers reported in ear-
lier studies (Gillespie et al. 1988, Visuri and Koskenvuo 1991). 
The reticuloendothelial system is especially loaded with wear 
debris (Langkamer et al. 1992, Case et al.1996). In vivo stud-
Table 3. Observed (Obs) numbers of cancer cases and standardized incidence ratios (SIR) with 95% confidence intervals (CI), by site and 
the time since the first total hip arthroplasty
Primary site   Time since operation
  0–2 years     3–10 years     11–20 years     > 20 years  
  Obs   SIR   95% CI   Obs   SIR   95% CI   Obs   SIR   95% CI   Obs   SIR   95% CI
All sites   492   0.80    0.73–0.87 a    2560    0.95    0.92–0.98 b    1697    0.99    0.94–1.03   97   0.93    0.75–1.12
Stomach   31    0.82    0.55–1.15   134    0.95    0.80–1.11   79   1.07   0.85–1.33  1  0.24    0.01–1.34
Colon    30    0.79    0.53–1.12   165    0.92    0.78–1.06  107    0.87    0.72–1.04   8    1.01    0.44–1.98
Rectum    19    0.72    0.43–1.12   111    0.98    0.81–1.17  59    0.86    0.66–1.11   4   0.98    0.27–2.51
Pancreas    21    0.78    0.48–1.18   111    0.95    0.78–1.13  62    0.82    0.63–1.05   7    1.41    0.57–2.90
Lung, trachea    40    0.48    0.34–0.65 a  204    0.66    0.57–0.75 a   115    0.70    0.57–0.82 a   9    1.00    0.46–1.89
Breast    69    1.02    0.79–1.29   264    0.96    0.85–1.08   177    1.08    0.93–1.24   5    0.49    0.16–1.14
Female genital 
   organs  40   0.97    0.69–1.32   152    0.95    0.80–1.10   82    0.88    0.70–1.09   5    0.88    0.29–2.05
Kidney    20   0.91    0.56–1.41   100    1.11    0.90–1.34   55    1.05    0.79–1.36   5    1.65    0.53–3.84
Prostate   56    0.81    0.61–1.05   433    1.10    1.00–1.20   335    1.14    1.02–1.26 b    19   1.16    0.70–1.80
Melanoma   10    0.88    0.42–1.61  50    0.99    0.74–1.30   33    0.97    0.67–1.36   4    1.84    0.50–4.71
Lymphoma,   
   leukemia  41  0.68   0.49–0.92   265   1.00   0.88–1.13  153  1.11  0.94–1.30   2  0.19   0.20–0.70 b
a p < 0.001; b p < 0.05. 80  Acta Orthopaedica 2010; 81 (1): 77–81
ies on lymphocytes in THA patients, both patients with TiAlV 
and with CoCr prostheses, showed that they had chromosomal 
aberrations (Stea et al. 2000, Doherty et al. 2001). In addition, 
patients with MP bearings had a reduced number of peripheral 
T lymphocytes (Granchi et al. 2003). In our study, lymphomas 
and leukemias showed slightly increased SIR values until 20 
years of follow-up, and after that a decrease to 0.19—but with 
only 2 cases observed and 10.5 cases expected. The incidence 
of sarcoma was low, and to our knowledge, our series did not 
include any tumor at the site of the prosthesis. Despite the vast 
number of implanted THAs, only 52 malignant tumors located 
close to an arthroplasty (46 sarcomas, 5 lymphomas, and 1 
epidermoid carcinoma) have been reported in the western lit-
erature (Lucas et al. 2001, Schuh et al. 2004, Visuri et al. 2006, 
Hsieh et al. 2007, Min et al. 2008). 
Until now, meta-analyses on the risk of cancer after THA 
have shown that the patients can effectively resist the geno-
toxic effects of Co and Cr particles and ions and the possible 
development of cancer (Visuri et al. 2003, Onega et. al 2006). 
Co and Cr are essential trace elements, and one can assume 
that the cells have inherited efficient repair systems for DNA 
damage caused by these elements (Reynolds et al. 2004). In 
addition,  macrophages  have  been  shown  to  counteract  the 
genotoxic  and  cytotoxic  effects  of  CoCr  particles  in  vitro 
(Papageorgiou et al. 2008). 
Our study with a mean follow-up time of 12.6 years did 
not show any all-site or site-specific risk of cancer in patients 
with conventional THA, and most THA patients will outlive 
any possible latent period for cancer. However, a 20–40-year 
latent period is known to be required for some solid malig-
nant tumors (zur Hausen 1996, Yates et al. 1997, Anttila et 
al. 1998). As this survey may have been too short to ascertain 
the risk of cancer in young patients expected to use their THA 
prostheses for more than 30 years, analyses with even longer 
follow-up times are still needed.
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